Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

51.61 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly on "Stock Split Watch": A Deep Dive into a Pharmaceutical Giant's Future

November 19, 2025

Indianapolis, IN – November 19, 2025 – Eli Lilly and Company (NYSE: LLY), the pharmaceutical titan, finds itself at the epicenter of market speculation, firmly placed on "stock split watch" as its...

Via MarketMinute

Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle? ↗

November 18, 2025

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line.

Via The Motley Fool

Can AI Drive Peloton's Comeback? ↗

November 18, 2025

The market is hopping with interesting news.

Via The Motley Fool

Topics Artificial Intelligence

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients ↗

November 18, 2025

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.

Via Benzinga

Oprah Winfrey-Backed Wellness Stock Stumbles As GLP-1 Boom Reshapes Consumer Habits: Growth Score Plummets ↗

November 18, 2025

Prominent weight-loss and wellness company, WW International Inc. (NASDAQ: WW), backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this...

Via Benzinga

Topics Bankruptcy

Price Over Earnings Overview: Novo Nordisk ↗

November 17, 2025

Via Benzinga

Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗

November 17, 2025

With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation.

Via Benzinga

Topics ETFs

Novo Nordisk Leans Into Affordability Amid Rising Competition ↗

November 17, 2025

Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.

Via Benzinga

Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control ↗

November 17, 2025

Novo Nordisk's new chair Lars Sorensen plans to add pharma expertise and address governance concerns after a major board overhaul backed by the company's foundation.

Via Benzinga

Omeros (OMER) Q3 2025 Earnings Call Transcript ↗

November 17, 2025

Omeros (OMER) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Derivatives Earnings

How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration ↗

November 17, 2025

Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.

Via Investor's Business Daily

Topics Government

Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound ↗

November 17, 2025

The Danish drugmaker has announced that this offer is applicable to cash-paying patients looking to purchase introductory doses of Wegovy and Ozempic.

Via Stocktwits

Topics Artificial Intelligence

This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000? ↗

November 17, 2025

Healthcare stocks have far outperformed the broader market over the past month.

Via The Motley Fool

Topics ETFs Government World Trade

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? ↗

November 16, 2025

Investors will be watching what Trump makes happen.

Via The Motley Fool

Topics Government

Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market ↗

November 14, 2025

Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the sell side are WBD, Bill.com and TuneIn.

Via Benzinga

Novo Nordisk Brings Back Former CEO To Lead Board ↗

November 14, 2025

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday.

Via Stocktwits

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Why Did Scholar Rock Soar 26% Today? ↗

November 14, 2025

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.

Via Stocktwits

Topics Earnings

Ozempic Maker Novo Nordisk Faces Board Shakeup ↗

November 14, 2025

Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market.

Via Benzinga

Is It Too Late to Buy Novo Nordisk After the Drop? ↗

November 14, 2025

Analysts still see 52% upside for Novo Nordisk -- find out whether its blockbuster drugs can spark a major rebound in 2025.

Via The Motley Fool

Why Is Everyone Talking About Novo Nordisk Stock? ↗

November 14, 2025

There is hardly a dull moment for the drugmaker these days.

Via The Motley Fool

Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO ↗

November 14, 2025

The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction.

Via Stocktwits

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗

November 13, 2025

Via Stocktwits

Korro Bio Early Trial Results Fall Short; Stock Hits New Low ↗

November 13, 2025

Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.

Via Benzinga

Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report ↗

November 13, 2025

CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game.

Via Stocktwits

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗

November 13, 2025

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

Via Benzinga

Mangoceuticals Shares Soar Pre-market After Partnering with Eli Lilly, Novo Nordisk To Sell Obesity Drugs ↗

November 13, 2025

The company has launched two programs, MangoRx Direct and PeachesRx Direct, to provide access to Lilly’s Zepbound and Novo’s Wegovy medicines.

Via Stocktwits

1 Incredible Reason to Buy LLY's Stock in November ↗

November 13, 2025

Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher.

Via The Motley Fool

Topics Government World Trade

Eli Lilly Soars: A Pharmaceutical Giant's Breakout Fueled by Blockbuster Drugs and Strategic Vision

November 12, 2025

INDIANAPOLIS, IN – November 12, 2025 – Eli Lilly and Company (NYSE: LLY) is experiencing a monumental stock breakout today, sending ripples across the global financial markets. The pharmaceutical...

Via MarketMinute

Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗

November 12, 2025

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today